298708-81-3
298708-81-3 性质
| 沸点 | 475.3±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.46±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：100 mg/mL (252.68 mM)；水：< 0.1 mg/mL（不溶） |
| 酸度系数(pKa) | 5.43±0.60(Predicted) |
| 形态 | 固体 |
| 颜色 | 浅黄至黄色 |
| InChI | 1S/C18H13ClF3N3O2/c1-8-14(18(26)27-2)15(11-4-3-9(20)5-12(11)19)25-17(24-8)16-13(22)6-10(21)7-23-16/h3-7,15H,1-2H3,(H,24,25)/t15-/m0/s1 |
| InChIKey | FVNJBPMQWSIGJK-HNNXBMFYSA-N |
| SMILES | CC1=C(C(OC)=O)[C@H](C2=C(Cl)C=C(F)C=C2)N=C(C3=NC=C(F)C=C3F)N1 |
298708-81-3 用途与合成方法
IC50&Target: 53 nM (HBV)
BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro . Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC 50 s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition.
BAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs.BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid.
298708-81-3 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-100029 | 298708-81-3 | 298708-81-3 | 5mg | 940 |
| 2026-09-15 | HY-100029 | 298708-81-3 | 298708-81-3 | 10 mM * 1 mLin DMSO | 1034 |
